Pharma Intermediate Erythromycin Thiocyanate CAS 7704-67-8

The development of China's API industry started later than developed countries and regions such as Europe and the United States, and there have been twists and turns in the development process. However, with the good industrial foundation established in China's fine chemical industry, the continuous cultivation and accumulation of talents, the continuous improvement of technical capabilities and the rapid development of the pharmaceutical industry as a whole, China's API industry has developed rapidly, and the API product structure has been iteratively optimized. At present, China has become the world's most important producer and exporter of raw material drugs.
It is understood that ampicillin sodium is a broad spectrum semi-synthetic penicillin. This product has strong antibacterial action against hemolytic streptococcus, Streptococcus pneumoniae and Staphylococcus penicillinase. It also has good antibacterial effect on Streptococcus viridis, and its effect on Enterococcus and Listeria is better than that of penicillin. This product has antibacterial activity against Corynebacterium diphtheriae, Bacillus anthracis, actinomyces, Haemophilus influenzae, Bordetella pertussis, Neisseria and other anaerobic bacteria except Bacteroides fragile. Some Proteus mirabilis, Escherichia coli, Salmonella and shigella bacteria are sensitive to this product.
For the ampicillin sodium "Chemical raw material Application Approval Notice" obtained by the company, North China Pharmaceutical said that it is a further supplement to its raw material products, enriches the company's product line, and will not have a significant impact on the company's current operating results.
The industry said that the API obtained the "Notification of Application for Approval of the listing of Chemical apis", indicating that the API meets the relevant requirements of domestic drug registration and can be sold in the domestic market. In recent years, a large number of domestic pharmaceutical companies have announced that the company's products have obtained the "Notification of Application for Approval of the listing of chemical raw materials", which is worthy of attention.
In addition to North China Pharmaceutical, Lukang Pharmaceutical announced on June 3 that febuxosta obtained the application approval notice for the listing of chemical raw materials. Febuxoat, a derivative of 2-arylthiazole, is a xanthine oxidase inhibitor that reduces serum uric acid concentration by inhibiting uric acid synthesis and can be used as a first-line uric-lowering agent in patients with gout. The company said that the Doxofylline API obtained the "Notification of Application for Approval of the Listing of Chemical apis", indicating that the API meets the relevant requirements of domestic drug registration and can be sold in the domestic market.